Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 45

Sort by

Sort Order Select

Journal Articles

Laboratories Can Reliably Detect Clinically Relevant Variants in the TP53 Gene below 10 % Allelic Frequency: A Multicenter Study of ERIC, the European Research Initiative on CLL

Sarka Pavlova, Jitka Malcikova, Lenka Radova, Silvia Bonfiglio, Jack B. Cowland, Christian Brieghel, Mette Klarskov Andersen, Maria Karypidou, Bella V Biderman, Michael Doubek, Gregory Lazarian, Inmaculada Rapado, Matthijs Vynck, Naomi Porret, Martin Andres, Dina Rosenberg, Dvora Sahar, Carolina Martinez-Laperche, Ismael Buño Borde, Andrew Hindley, Julio Bravo Sánchez, José García-Marco, Alicia Serrano, Blanca Ferrer Lores, Concepción Fernández-Rodriguez, Beatriz Bellosillo, Stephan Stilgenbauer, Eugen Tausch, Hero Nikdin, Fiona Quinn, Emer Atkinson, Lisette Van De Corput, Cafer Yildiz, Cristina Bilbao, Yanira Florido, Christian Thiede, Caroline Schuster, Anastazja Stoj, Sylwia Czekalska, Anastasia Chatzidimitriou, Stamatia Laidou, Audrey Bidet, Charles Dussiau, Friedel Nollet, Giovanna Piras, Tereza Borosova, Terezia Kurucova, Maria Monne, Svetlana Smirnova, Evgeny Nikitin, Ivan Sloma, Marie-Helene Delfau, Laetitia Largeaud, Loic Ysebaert, Peter J. M. Valk, Amy Christian, Renata Walewska, Marta Sebastião, Maria Gomes da Silva, Piero Galieni, Mario Angelini, Davide Rossi, Valeria Spina, Sónia Matos, Vânia Martins, David Donaldson, Tomasz Stoklosa, Monika Pepek, Panagiotis Baliakas, Rafa Andreu, Irene Luna, Tiina Kahre, Ülle Murumets, Sophie Laird, Daniel Ward, Miguel Alcoceba, Ana Balanzategui, Lydia Scarfo, Francesca Gandini, Ettore Zapparoli, Adoracion Blanco, Pau Abrisqueta Costa, Ana E. Rodriguez, Maria Rocio Benito Sanchez, Frédéric Davi, Clothilde Bravetti, Paula Gameiro, Joaquin Martinez-Lopez, Barbara Tazon, Fanny Baran-Marszak, Zadie Davies, Mark Caterwood, Andrey B Sudarikov, Richard Rosenquist, Carsten Utoft Niemann, Kostas Stamatopoulos, Paolo Ghia, Sarka Pospisilova

Blood (2023) 142 (Supplement 1): 200.

https://doi.org/10.1182/blood-2023-173235

Published: 2023

Journal Articles

Clonal Targeting of DNA Damage Response Pathways Eradicates Myeloproliferative Neoplasms

Monika Toma, Margaret Nieborowska-Skorska, Adam Karami, Monika Pepek, Tomasz Stoklosa, Tomasz Skorski

Blood (2023) 142 (Supplement 1): 120.

https://doi.org/10.1182/blood-2023-174280

Published: 2023

Journal Articles

Clonal Hematopoiesis with Somatic Mutations in "AYA" Generation of Patients with Chronic Myeloid Leukemia

Jitka Koblihova, Vaclava Polivkova, Adela Benesova, Hana Zizkova, Nikola Curik, Monika Pepek, Tomasz Stoklosa, MD PhD, Marketa Markova Stastna, Hana Klamová, Dana Srbova, Katerina Machova

Blood (2020) 136 (Supplement 1): 23–24.

https://doi.org/10.1182/blood-2020-140725

Published: 2020

Journal Articles

ASXL1 Mutations Detectable at Diagnosis May Predict Response to Imatinib in Patients with Chronic Myeloid Leukemia

Marcin M Machnicki, MSc, Monika Pepek, MSc, Iwona Solarska, PhD, Joanna Niesiobedzka-Krezel, MD PhD, Ilona Seferynska, MD PhD, Joanna Gora Tybor, MD PhD, Magdalena Zawada, PhD, Tomasz Sacha, MD PhD, Waldemar Sawicki, MD PhD, Ewa Wasilewska, MD PhD, Katarzyna Pruszczyk, MD, Malgorzata Rydzanicz, PhD, Rafal Ploski, MD PhD, Tomasz Skorski, MD PhD, Tomasz Stoklosa, MD PhD

Blood (2019) 134 (Supplement_1): 4148.

https://doi.org/10.1182/blood-2019-129834

Published: 2019

Journal Articles

Predictive Significance of Selected Gene Mutations Identified Using Next Generation Sequencing in Relapsed and Refractory Chronic Lymphocytic Leukemia Patients Treated with Ibrutinib

Marcin M Machnicki, MSc, Patryk Górniak, Monika Pepek, MSc, Agnieszka Szymczyk, Elżbieta Iskierka-Jażdżewska, Pawel Steckiewicz, Aleksandra Bluszcz, Malgorzata Rydzanicz, PhD, Marek Hus, Rafal Ploski, MD PhD, Przemyslaw Juszczynski, Prof., MD PhD, Tomasz Stoklosa, MD PhD, Krzysztof Jamroziak, MD PhD, Bartosz Pula

Blood (2019) 134 (Supplement_1): 5456.

https://doi.org/10.1182/blood-2019-124693

Published: 2019

Journal Articles

The Role of Shelterin Complex and Post-Translational Non-Enzymatic Modification in Telomere Maintenance in Chronic Myeloid Leukemia

Anna Deregowska, MSc, Katarzyna Pruszczyk, MD, Iwona Solarska, PhD, Ilona Seferynska, MD PhD, Marek Dudzinski, MD, Maciej Wnuk, PhD, Tomasz Stoklosa, MD PhD

Blood (2018) 132 (Supplement 1): 5426.

https://doi.org/10.1182/blood-2018-99-112879

Published: 2018

Journal Articles

Tyrosine kinase inhibitor–induced defects in DNA repair sensitize FLT3(ITD)-positive leukemia cells to PARP1 inhibitors

Blood (2018) 132 (1): 67–77.

https://doi.org/10.1182/blood-2018-02-834895

Published: 2018

Includes: Supplemental data

Journal Articles

Concomitant Medications and Comorbidities Affect Early Response in CML Patients Treated with Imatinib: A Retrospective Analysis of 340 Patients from the Polish Adult Leukemia Group (PALG) Registry

Joanna Gora Tybor, Tomasz Sacha, Joanna Waclaw, Joanna Niesiobedzka-Krezel, Olga Grzybowska-Izydorczyk, Ewa Medras, Izabela Deren-Wagemann, Elzbieta Patkowska, Ilona Seferynska, Krzysztof Lewandowski, Anna Wache, Beata Blajer-Olszewska, Marzena Watek, Ewa Wasilewska, Tomasz Stoklosa, Krzysztof Warzocha, Krzysztof Jamroziak

Blood (2017) 130 (Supplement 1): 2887.

https://doi.org/10.1182/blood.V130.Suppl_1.2887.2887

Published: 2017

Journal Articles

Tyrosine Kinase Inhibitor-Induced Defects in DNA Repair Sensitize FLT3(ITD)-Positive Acute Myeloid Leukemia Quiescent and Proliferative Cells to PARP Inhibitors

Blood (2017) 130 (Supplement 1): 2635.

https://doi.org/10.1182/blood.V130.Suppl_1.2635.2635

Published: 2017

Journal Articles

Detailed Clinical, Immunological and Molecular Analysis of NOTCH1 , SF3B1 and MYD88 mutations in Chronic Lymphocytic Leukemia Patients Reveals Accumulation of Negative Prognostic Features in NOTCH1 and SF3B1 mutated Individuals

Maciej Putowski, Marta Podgórniak, Marta Piróg, Joanna Knap, Jacek Zawislak, Joanna Zaleska, Ewelina Zakrzewska, PhD, Joanna Purkot, Agnieszka Karczmarczyk, PhD, Paulina Wlasiuk, PhD, Waldemar Tomczak, MD PhD, Edyta Cichocka, MD PhD, Edyta Subocz, MD, Janusz Halka, MD PhD, Daria Zawirska, MD PhD, Witold Jeleniewicz, Andrzej Stepulak, MD PhD, Tomasz Stoklosa, MD PhD, Krzysztof Giannopoulos, MD PhD

Blood (2016) 128 (22): 5570.

https://doi.org/10.1182/blood.V128.22.5570.5570

Published: 2016

Journal Articles

Role of Shelterin Complex and Alternative Telomere Lengthening in Genomic Instability and Disease Progression in Chronic Myeloid Leukemia

Tomasz Stoklosa, MD PhD, Anna Deregowska, Katarzyna Pruszczyk, Iwona Solarska, PhD, Marcin M Machnicki, Jagoda Adamczyk, Ilona Seferynska, Anna Lewinska, PhD, Maciej Wnuk, PhD

Blood (2016) 128 (22): 1880.

https://doi.org/10.1182/blood.V128.22.1880.1880

Published: 2016

Journal Articles

Normal ABL1 is a tumor suppressor and therapeutic target in human and mouse leukemias expressing oncogenic ABL1 kinases

Yashodhara Dasgupta, Mateusz Koptyra, Grazyna Hoser, Kanchan Kantekure, Darshan Roy, Barbara Gornicka, Margaret Nieborowska-Skorska, Elisabeth Bolton-Gillespie, Sabine Cerny-Reiterer, Markus Müschen, Peter Valent, Mariusz A. Wasik, Christine Richardson, Oliver Hantschel, Heiko van der Kuip, Tomasz Stoklosa, Tomasz Skorski

Blood (2016) 127 (17): 2131–2143.

https://doi.org/10.1182/blood-2015-11-681171

Published: 2016

Includes: Supplemental data

Journal Articles

Somatic Mutations in Commonly Mutated Genes in Myeloid Malignancies May Preexist or Arise in the Course of Chronic Myeloid Leukemia - Different Scenarios of Progression Revealed By Targeted Next-Generation Sequencing

Marcin M Machnicki, Iwona Solarska, PhD, Rafal Ploski, MD PhD, Ilona Seferynska, MD PhD, Tomasz Stoklosa, MD PhD

Blood (2015) 126 (23): 2771.

https://doi.org/10.1182/blood.V126.23.2771.2771

Published: 2015

Journal Articles

HIF1-Alpha and MYC Transcription Factor Signatures in B-Cell Acute Lymphoblastic Leukemia Are Associated with Positive Minimal Residual Disease Status: Therapeutic Implications

Tomasz Sewastianik, MSc, Patryk Gorniak, PhD, Przemyslaw Kiliszek, MSc, Anna Polak, MSc, Emilia Bialopiotrowicz, PhD, Ewa Jablonska, PhD, Maciej Szydlowski, PhD, Ewa Lech-Maranda, MD PhD, Katarzyna Borg, PhD, Hanna Makuch-Lasica, MSc, Adam Zabek, MSc, Piotr Mlynarz, PhD, Tomasz Stoklosa, MD PhD, Sebastian Giebel, MD PhD, Krzysztof Warzocha, MD PhD, Przemyslaw Juszczynski, MD PhD

Blood (2015) 126 (23): 1436.

https://doi.org/10.1182/blood.V126.23.1436.1436

Published: 2015

Journal Articles

HDAC Inhibitors As Potential New Agents Improving the Efficacy of Monoclonal Antibodies

Malgorzata Bobrowicz, MSc, Michal Dwojak, DMD, Agata Malenda, MD PhD, Kamil Bojarczuk, MSc, Marta Siernicka, MSc, Beata Pyrzynska, PhD, Ewa Lech-Maranda, MD PhD, Tomasz Stoklosa, MD PhD, Magdalena Winiarska, PhD, Jakub Golab, MD PhD

Blood (2014) 124 (21): 3641.

https://doi.org/10.1182/blood.V124.21.3641.3641

Published: 2014

Journal Articles

Gene Expression and Mutation Analysis (GEMA) –Guided Precision Medicine Targeting PARP1 to Induce Synthetic Lethality in DNA-PK –Deficient Quiescent and BRCA-Deficient Proliferating Leukemia Stem and Progenitor Cells

Margaret Nieborowska-Skorska, MD PhD, Katherine Sullivan, Paulina Podszywalow-Bartnicka, Grazyna Hoser, PhD, Elisabeth Bolton-Gillespie, Kimberly Cramer-Morales, Artur Slupianek, PhD, Chun Zhou, PhD, Sabine Cerny-Reiterer, DVM, Tomasz Stoklosa, MD PhD, Stephen M. Sykes, PhD, Peter Valent, MD, Curt I. Civin, MD, Markus Muschen, MD PhD, Mark D. Minden, MD PhD, Kolja Eppert, PhD, Tomasz Skorski, MD PhD

Blood (2014) 124 (21): 480.

https://doi.org/10.1182/blood.V124.21.480.480

Published: 2014

Journal Articles

Effects of First and Next-Generation Tyrosine Kinase Inhibitors on Telomere-Mediated Chromosomal Instability in Chronic Myeloid Leukemia Cells

Tomasz Stoklosa, MD PhD, Anna Deregowska, Joanna Drzewinska-Chanko, PhD, Joanna Barankiewicz, MD, Machnicki M Marcin, Pruszczyk Katarzyna, Maciej Wnuk, PhD

Blood (2014) 124 (21): 5510.

https://doi.org/10.1182/blood.V124.21.5510.5510

Published: 2014

Journal Articles

Differential Expression of BIRC Family Genes In The Course Of Chronic Myeloid Leukemia – BIRC3 and BIRC8 As Potential New Candidates To Identify Disease Progression

Eliza Glodkowska-Mrowka, MD, Iwona Solarska, PhD, Piotr Mrowka, PhD, Katarzyna Bajorek, MSc, Joanna Niesiobedzka-Krezel, MD, Ilona Seferynska, MD, PhD, Katarzyna Borg, PhD, Tomasz Stoklosa, MD, PhD

Blood (2013) 122 (21): 2718.

https://doi.org/10.1182/blood.V122.21.2718.2718

Published: 2013

Journal Articles

Normal ABL1 Is a Tumor Suppressor and Therapeutic Target In BCR-ABL1–positive Leukemias

Yashodhara Dasgupta, Mateusz Koptyra, PhD, Margaret Nieborowska-Skorska, MD, PhD, Elisabeth Bolton Gillespie, PhD, Tomasz Stoklosa, MD, PhD, Grazyna Hoser, PhD, Mariusz Wasik, MD, Markus Muschen, Christine Richardson, PhD, Tomasz Skorski, MD, PhD

Blood (2013) 122 (21): 1466.

https://doi.org/10.1182/blood.V122.21.1466.1466

Published: 2013

Journal Articles

Genomic instability may originate from imatinib-refractory chronic myeloid leukemia stem cells

Elisabeth Bolton-Gillespie, Mirle Schemionek, Hans-Ulrich Klein, Sylwia Flis, Grazyna Hoser, Thoralf Lange, Margaret Nieborowska-Skorska, Jacqueline Maier, Linda Kerstiens, Mateusz Koptyra, Martin C. Müller, Hardik Modi, Tomasz Stoklosa, Ilona Seferynska, Ravi Bhatia, Tessa L. Holyoake, Steffen Koschmieder, Tomasz Skorski

Blood (2013) 121 (20): 4175–4183.

https://doi.org/10.1182/blood-2012-11-466938

Published: 2013

Includes: Supplemental data

NARROW

Laboratories Can Reliably Detect Clinically Relevant Variants in the TP53 Gene below 10 % Allelic Frequency: A Multicenter Study of ERIC, the European Research Initiative on CLL

Clonal Targeting of DNA Damage Response Pathways Eradicates Myeloproliferative Neoplasms

Clonal Hematopoiesis with Somatic Mutations in "AYA" Generation of Patients with Chronic Myeloid Leukemia

ASXL1 Mutations Detectable at Diagnosis May Predict Response to Imatinib in Patients with Chronic Myeloid Leukemia

Predictive Significance of Selected Gene Mutations Identified Using Next Generation Sequencing in Relapsed and Refractory Chronic Lymphocytic Leukemia Patients Treated with Ibrutinib

The Role of Shelterin Complex and Post-Translational Non-Enzymatic Modification in Telomere Maintenance in Chronic Myeloid Leukemia

Tyrosine kinase inhibitor–induced defects in DNA repair sensitize FLT3(ITD)-positive leukemia cells to PARP1 inhibitors

Concomitant Medications and Comorbidities Affect Early Response in CML Patients Treated with Imatinib: A Retrospective Analysis of 340 Patients from the Polish Adult Leukemia Group (PALG) Registry

Tyrosine Kinase Inhibitor-Induced Defects in DNA Repair Sensitize FLT3(ITD)-Positive Acute Myeloid Leukemia Quiescent and Proliferative Cells to PARP Inhibitors

Detailed Clinical, Immunological and Molecular Analysis of NOTCH1 , SF3B1 and MYD88 mutations in Chronic Lymphocytic Leukemia Patients Reveals Accumulation of Negative Prognostic Features in NOTCH1 and SF3B1 mutated Individuals

Role of Shelterin Complex and Alternative Telomere Lengthening in Genomic Instability and Disease Progression in Chronic Myeloid Leukemia

Normal ABL1 is a tumor suppressor and therapeutic target in human and mouse leukemias expressing oncogenic ABL1 kinases

Somatic Mutations in Commonly Mutated Genes in Myeloid Malignancies May Preexist or Arise in the Course of Chronic Myeloid Leukemia - Different Scenarios of Progression Revealed By Targeted Next-Generation Sequencing

HIF1-Alpha and MYC Transcription Factor Signatures in B-Cell Acute Lymphoblastic Leukemia Are Associated with Positive Minimal Residual Disease Status: Therapeutic Implications

HDAC Inhibitors As Potential New Agents Improving the Efficacy of Monoclonal Antibodies

Gene Expression and Mutation Analysis (GEMA) –Guided Precision Medicine Targeting PARP1 to Induce Synthetic Lethality in DNA-PK –Deficient Quiescent and BRCA-Deficient Proliferating Leukemia Stem and Progenitor Cells

Effects of First and Next-Generation Tyrosine Kinase Inhibitors on Telomere-Mediated Chromosomal Instability in Chronic Myeloid Leukemia Cells

Differential Expression of BIRC Family Genes In The Course Of Chronic Myeloid Leukemia – BIRC3 and BIRC8 As Potential New Candidates To Identify Disease Progression

Normal ABL1 Is a Tumor Suppressor and Therapeutic Target In BCR-ABL1–positive Leukemias

Genomic instability may originate from imatinib-refractory chronic myeloid leukemia stem cells

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only